Cargando…

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus

OBJECTIVE: To evaluate the clinical utility of the multianalyte assay panel (MAP), commercially known as AVISE Lupus test (Exagen Inc.), in patients suspected of SLE. METHODS: A systematic review of medical records of ANA-positive patients with a positive (>0.1) or negative (<−0.1) MAP score w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alexander, Roberta Vezza, Rey, Daniel Scott, Conklin, John, Domingues, Vinicius, Ahmed, Mansoor, Qureshi, Jazibeh, Weinstein, Arthur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Biomarker Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276296/ https://www.ncbi.nlm.nih.gov/pubmed/34253650 http://dx.doi.org/10.1136/lupus-2021-000528

Ejemplares similares

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
por: Wallace, Daniel J, et al.
Publicado: (2019)

A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2021)

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
por: Conklin, John, et al.
Publicado: (2022)

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements
por: Putterman, Chaim, et al.
Publicado: (2014)

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products
por: Wallace, Daniel J, et al.
Publicado: (2016)

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
por: Buyon, Jill, et al.
Publicado: (2016)

The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus
por: Mossell, James, et al.
Publicado: (2016)

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018)

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE
por: Petri, Michelle A, et al.
Publicado: (2019)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus
por: Petri, Michelle A, et al.
Publicado: (2020)

Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020)

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2018)

Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus
por: Mackay, Meggan, et al.
Publicado: (2015)

Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children
por: Brunner, Hermine I, et al.
Publicado: (2014)

Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection
por: Mackay, Meggan, et al.
Publicado: (2016)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019)

Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus
por: Sadras, Vignesh, et al.
Publicado: (2020)

Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus
por: Cornwell, MacIntosh Grant, et al.
Publicado: (2021)

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
por: Ruacho, Guillermo, et al.
Publicado: (2022)

Elevation of serum anti–glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus
por: Matsueda, Yu, et al.
Publicado: (2018)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus
por: Raymond, Warren David, et al.
Publicado: (2021)

Differential expression of antibodies to NMDA receptor in anti-NMDA receptor encephalitis and in neuropsychiatric systemic lupus erythematosus
por: Hirohata, Shunsei, et al.
Publicado: (2019)

RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin
por: Merola, Joseph F, et al.
Publicado: (2021)

Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus
por: Fasano, Serena, et al.
Publicado: (2022)

Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up
por: Schoindre, Yoland, et al.
Publicado: (2014)

Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density
por: Shevchuk, Sergii, et al.
Publicado: (2023)

Knowledge-Driven Approaches to Create the MTox700+ Metabolite Panel for Predicting Toxicity
por: Sostare, Elena, et al.
Publicado: (2022)

Cell-bound complement activation products in SLE
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2017)

Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies
por: Brunekreef, Tammo, et al.
Publicado: (2021)

Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus
por: Anderson, Erik W, et al.
Publicado: (2021)

Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma
por: Firpo, Matthew A., et al.
Publicado: (2023)

Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus
por: Nielsen, Christoffer T, et al.
Publicado: (2014)

ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies
por: Chen, Der-Yuan, et al.
Publicado: (2021)

Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?
por: Raj, Naveen, et al.
Publicado: (2016)

Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE
por: Domingues, Vinicius, et al.
Publicado: (2016)

Complement and systemic lupus erythematosus
por: Walport, Mark J
Publicado: (2002)

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial
por: McDonald, Stephen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9i4v53mh9h2jkdj88hb9s192bt